Omni Bio Pharmaceutical Inc

Omni Bio Pharmaceutical — Jefferies Global Life Sciences Conference 2010

27 slides from Omni Bio Pharmaceutical's conference presentation, Jun 11, 2010

  1. Slide 1: Jefferies Global Life Sciences Conference

    Slide 1: Jefferies Global Life Sciences Conference

    Jefferies Global Life Sciences Conference New York, NY June 11, 2010 Omni Bio Pharmaceutical, Inc (OTCBB:OMBP)

  2. Slide 2: Forward-Looking Statements

    Slide 2: Forward-Looking Statements

    Forward-Looking Statements Except for the historical information contained herein, the matters discussed in this presentation are forward-looking statements. The forward-looking statements in this presentation are based on information available to us as of the date any such statements are made and w

  3. Slide 3: Omni Bio Pharmaceutical, Inc.

    Slide 3: Omni Bio Pharmaceutical, Inc.

    Omni Bio Pharmaceutical, Inc. Applying approved and novel products for the treatment of health conditions such as Type 1 and Type 2 diabetes, acute or chronic transplant rejection and bacterial and viral infection

  4. Slide 4: Management team

    Slide 4: Management team

    Acting Chief Executive Officer: Charles A. Dinarello, MD Member of the National Academy of Sciences -Listed by Institute for Scientific Information as the world’s fourth most cited scientist for 20 years (1982-2003). Numerous international awards including 2009 Crafoord Prize (Royal Swedish Academy)

  5. Slide 5: Objectives and Approach

    Slide 5: Objectives and Approach

    To develop, patent, and commercialize treatment of novel indications with FDA approved drugs with large market opportunities. FDA approval for an existing drug means significantly reduced time to market for new indications with limited safety issues to overcome. FDA approval will likely focus on eff

  6. Slide 6: Omni Target Market Populations

    Slide 6: Omni Target Market Populations

    Type 1 Diabetes -15,000-18,000 Type 1 juvenile diabetics are diagnosed in the USA per year (40 per day) No alternative to insulin therapy exists. Total Type 1 population of 2 million patients including adults. Type 2 Diabetes -(Total population currently estimated at 24 million in the USA) Treatment

  7. Slide 7: IP Portfolio

    Slide 7: IP Portfolio

    Omni is the licensee of 3 patent portfolios from the University of Colorado comprising 1 issued and 16 filed patents 1. An issued patent, a notice of allowance and additional patent applications for the treatment of viral diseases including Influenza and HIV-1. 2. Patent applications for the treatme

  8. Slide 8: Patent Portfolio and Business Approach

    Slide 8: Patent Portfolio and Business Approach

    Methods of use for alpha 1 antitrypsin (AAT)-based and AAT Derivative based treatment of diabetes (Type 1 and Type2). Composition of matter and methods of use for AAT-based treatment of viral and bacterial disorders. Methods of use for AAT-based and AAT derivative based treatment of graft versus hos

  9. Slide 9: Omni Bio Pharmaceuticals to Initiate Human Clinical Trial of Alpha 1 on Type 1 Diabetes

    Slide 9: Omni Bio Pharmaceuticals to Initiate Human Clinical Trial of Alpha 1 on Type 1 Diabetes

    + Omni Bio Pharmaceuticals ToInitiate Human Clinical Trial of Aloha 1 on Type 1 Diabetes

  10. Slide 10: Alpha 1 Antitrypsin (AAT) and Omni

    Slide 10: Alpha 1 Antitrypsin (AAT) and Omni

    AAT is a naturally occurring human serum protein. FDA approved and currently is prescribed for emphysema and chronic obstructive pulmonary disorder (COPD) in AAT deficient patients. As a current regimen for the treatment of emphysema and COPD, AAT is administered once a week by infusion. AAT has one

  11. Slide 11: AAT - A naturally occurring protein without the side effects of other agents

    Slide 11: AAT - A naturally occurring protein without the side effects of other agents

    AAT: Inhibits destructive enzymes such as proteinase-3 Anti-migratory Anti-Complement Prevents maturation of antigen presenting cells Induces T-regulatory cells Inhibits responses to inflammatory cytokines Increases production of anti-inflammatory molecules AAT - A naturally occurring protein withou

  12. Slide 12: Animal Studies - Diabetes

    Slide 12: Animal Studies - Diabetes

    At clinically relevant doses, AAT protects the insulin-producing beta cells against toxic agents (Proceedings of the National Academy of Sciences , 2005 and 2008). AAT protects HUMAN islet cells against the toxic effects of cytokines. Cytokines are produced in Type 1 and Type 2 diabetes and are a ma

  13. Slide 13: Human Islets: Effect of cytokine induced toxicity and protection by AAT

    Slide 13: Human Islets: Effect of cytokine induced toxicity and protection by AAT

    disintegrating, dying islets, as takes place in vivo by immune attack intact, living islets protected by AAT during an immune attack Presence of IL-1 b /IFN g + Vehicle Presence of IL-1 b /IFN g + AAT Human Islets: Effect of cytokine induced toxicity and protection by AAT

  14. Slide 14: Type 1 Diabetes Trial

    Slide 14: Type 1 Diabetes Trial

    Barbara Davis Center for Childhood Diabetes at the University of Colorado Hospital-Denver, Anschutz Medical Campus Recently diagnosed Type 1 diabetics 8 weekly infusions of AAT at the commencement of the trial, then the patients symptoms will be monitored for two years Recognized endpoints (same as

  15. Slide 15: AAT in Type 2 diabetes beta-cell loss

    Slide 15: AAT in Type 2 diabetes beta-cell loss

    AAT in salvaging the loss of the insulin-producing beta-cell in Type 2 diabetes In Type 2 diabetes, progressive loss of functional insulin-producing beta-cells takes place due to IL-1b produced in the fat that enters the islet Blocking IL-1b restores function and lowers hyperglycemia AAT blocks IL-1

  16. Slide 16: Principal Investigator at the University of Colorado

    Slide 16: Principal Investigator at the University of Colorado

    Leland Shapiro, MD , FACP Associate Professor of Medicine University of Colorado Certified by American Board of Internal Medicine University of Massachusetts School of Medicine Broadly published researcher — — — — Principal Investigator at the University of Colorado, Anschutz Medical Campus

  17. Slide 17: Influenza

    Slide 17: Influenza

    In the U.S. each year: 10-20% of population infected (30-60 million people) Children and the Elderly are at risk groups 114,000 hospitalizations 36,000 deaths Annual Economic Burden of approximately $3-15 billion. — — — — — — Influenza

  18. Slide 18: Effect of 1918 Pandemic Flu on Population

    Slide 18: Effect of 1918 Pandemic Flu on Population

    Effect of 1918 Pandemic Flu on Population

  19. Slide 19: AAT protects cells from influenza infection

    Slide 19: AAT protects cells from influenza infection

    Influenza alone Influenza + AAT AAT protects cells from influenza infection

  20. Slide 20: AAT inhibits influenza production in infected cells

    Slide 20: AAT inhibits influenza production in infected cells

    AAT inhibits influenza production in infected cells (10 experiments + replicates)

  21. Slide 21: Survival in AAT transgenic mice challenged with live influenza

    Slide 21: Survival in AAT transgenic mice challenged with live influenza

    Survival in AAT transgenic mice challenged with live influenza (p=0.0007)

  22. Slide 22: AAT deficiency is a risk factor for flu infection in humans

    Slide 22: AAT deficiency is a risk factor for flu infection in humans

    22 AAT deficiency is a risk factor for FLU infection in humans p=0.0012

  23. Slide 23: AAT Impact on Influenza

    Slide 23: AAT Impact on Influenza

    • Both a treatment and preventative product • Potentially broad spectrum treatment for different types of influenza including “bird FLU”, “swine Flu (H1N1)”, and “weaponized” FLU • Impervious to mutation-induced resistance: AAT is still effective even if the virus changes or mutates • Compatible wit

  24. Slide 24: AAT-based studies: Immediate Opportunities and Status

    Slide 24: AAT-based studies: Immediate Opportunities and Status

    Indication Laboratory studies in cells Animal studies Human studies Clinical trial Anthrax + + = NA Influenza + + + = Diabetes Type 1 + + + Pending Diabetes Type 2 + + = = Graft rejection + + + = Tuberculosis (TB) + + = = + = completed or in process; - = has not been completed AAT-based studies: Imm

  25. Slide 25: Business Summary

    Slide 25: Business Summary

    Broad Intellectual Property Position In Major Markets Diabetes Influenza and Bacterial diseases 3 Licenses 16 Patents Pending, 1 US Patent Issued Upcoming AAT Clinical Trials in Diabetes FDA approved pharmaceutical applied to new and large markets Outsourced business model requiring l ow overhead, c

  26. Slide 26: Omni Bio Pharmaceutical, Inc. Corporate Information

    Slide 26: Omni Bio Pharmaceutical, Inc. Corporate Information

    Omni Bio Pharmaceutical, Inc Corporate Information: OTCBB Symbol: OMBP Fiscal Year End: March 31 Outstanding Shares as of March 31, 2010: 28 Million Common Stock Equivalents (3/31/2010): 11.5 Million Corporate and IP Counsel: Faegre & Benson Auditors: Hein and Associates

  27. Slide 27: Thank you for your interest

    Slide 27: Thank you for your interest

    Thank you for your interest

Source: SEC EDGAR · 8-K filed Jun 11, 2010

More decks from Omni Bio Pharmaceutical Inc